Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $18.00 | Buy | H.C. Wainwright |
| 1/21/2025 | $17.00 | Buy | UBS |
| 3/14/2024 | $16.00 → $20.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2024 | $22.00 | Outperform | Leerink Partners |
| 11/10/2023 | $11.00 | Overweight | Cantor Fitzgerald |
| 8/24/2023 | $5.00 → $6.00 | Underweight → Equal-Weight | Morgan Stanley |
| 2/22/2023 | $10.00 | Buy | Lake Street |
| 4/6/2022 | $13.00 | Outperform | Wolfe Research |
10-Q - NeuroPace Inc (0001528287) (Filer)
8-K - NeuroPace Inc (0001528287) (Filer)
SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)
-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive
--Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures-- --CY 2026 Outpatient Prospective Payment System (OPPS) Final Rule moves RNS replacement procedures to highest-paying neurostimulator APC-- NeuroPace, Inc. (NASDAQ:NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicare reimbursement updates for the RNS® System under both the CY 2026 OPPS and Medicare PFS final rules. In the CY 2026 Medicare PFS final rule, the Centers for Medicare & Medicaid Services (CMS) significantly increased professional payment for neurosurge
-- Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth -- -- Increased full-year 2025 revenue guidance to between $97 million and $98 million and gross margin guidance to between 76% and 77% -- -- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Financial Highlights Total revenue of $27.4 million, representing growth of 30% compared to the thir
H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00
UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00
Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously
4 - NeuroPace Inc (0001528287) (Issuer)
4 - NeuroPace Inc (0001528287) (Issuer)
4 - NeuroPace Inc (0001528287) (Issuer)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma
-- Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth -- -- Increased full-year 2025 revenue guidance to between $97 million and $98 million and gross margin guidance to between 76% and 77% -- -- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Financial Highlights Total revenue of $27.4 million, representing growth of 30% compared to the thir
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event at https://events.q4inc.com/attendee/831496029. Individuals interested in participating in the call via telephone may access the call by dialing + 1 (800) 715-9871 and referencing Conference ID 8467256. The
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Second Quarter